Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Neoadjuvant nivolumab with gemcitabine and cisplatin followed by adjuvant nivolumab for previously-untreated muscle-invasive bladder cancer	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Urological Cancer	2023	View \| Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Oncology , Urological Cancer	2021	View \| Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line	Oportuzumab monatox (Vicinium; VB4-845; Proxinium)	Bladder cancer	Urological Cancer	2020	View \| Download
Pembrolizumab and chemoradiation for treating muscle-invasive, non-metastatic bladder cancer	Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2023	View \| Download
Pembrolizumab perioperative therapy with neoadjuvant chemotherapy for treating cisplatin eligible muscle-invasive bladder cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2022	View \| Download
Pembrolizumab with Bacillus Calmette-Guerin for treating high-risk non-muscle invasive bladder cancer	Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2023	View \| Download